Cargando…

A human natural antibody to adenocarcinoma that inhibits tumour cell migration.

We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMA...

Descripción completa

Detalles Bibliográficos
Autores principales: Koda, K., Nakajima, N., Saito, N., Yasutomi, J., McKnight, M. E., Glassy, M. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063195/
https://www.ncbi.nlm.nih.gov/pubmed/9823972
_version_ 1782137287133364224
author Koda, K.
Nakajima, N.
Saito, N.
Yasutomi, J.
McKnight, M. E.
Glassy, M. C.
author_facet Koda, K.
Nakajima, N.
Saito, N.
Yasutomi, J.
McKnight, M. E.
Glassy, M. C.
author_sort Koda, K.
collection PubMed
description We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMAbs, only one, termed SK1, an IgM, was adenocarcinoma specific in the immunohistochemical study. The antigen recognized by SK1 (Ag-SK1) was a glycoprotein with a molecular weight of 42-46 kDa. The expression of Ag-SK1 on carcinoma cells varied according to the cell growth periods but was independent of cell cycle state as elucidated by two-colour fluorescence-activated cell sorter (FACS) analysis. A dot-blot analysis showed that the concentration of Ag-SK1 per total protein differed considerably among eight colon carcinoma cells examined and that the difference was closely correlated with the invasion capacity of the cells as assessed by a microchemotaxis assay. Furthermore, up to 87% of cell migration was inhibited by SK1 in a dose-dependent manner. These data suggested that Ag-SK1 is metabolized and expressed on highly invasive carcinoma cells. In addition, it appears that, although rare, some patients do mount an anti-cancer antigen response in their draining lymph nodes. A HuMAb such as SK1 may be a good candidate for the treatment of cancer invasion and metastasis. IMAGES:
format Text
id pubmed-2063195
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20631952009-09-10 A human natural antibody to adenocarcinoma that inhibits tumour cell migration. Koda, K. Nakajima, N. Saito, N. Yasutomi, J. McKnight, M. E. Glassy, M. C. Br J Cancer Research Article We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMAbs, only one, termed SK1, an IgM, was adenocarcinoma specific in the immunohistochemical study. The antigen recognized by SK1 (Ag-SK1) was a glycoprotein with a molecular weight of 42-46 kDa. The expression of Ag-SK1 on carcinoma cells varied according to the cell growth periods but was independent of cell cycle state as elucidated by two-colour fluorescence-activated cell sorter (FACS) analysis. A dot-blot analysis showed that the concentration of Ag-SK1 per total protein differed considerably among eight colon carcinoma cells examined and that the difference was closely correlated with the invasion capacity of the cells as assessed by a microchemotaxis assay. Furthermore, up to 87% of cell migration was inhibited by SK1 in a dose-dependent manner. These data suggested that Ag-SK1 is metabolized and expressed on highly invasive carcinoma cells. In addition, it appears that, although rare, some patients do mount an anti-cancer antigen response in their draining lymph nodes. A HuMAb such as SK1 may be a good candidate for the treatment of cancer invasion and metastasis. IMAGES: Nature Publishing Group|1 1998-11 /pmc/articles/PMC2063195/ /pubmed/9823972 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Koda, K.
Nakajima, N.
Saito, N.
Yasutomi, J.
McKnight, M. E.
Glassy, M. C.
A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
title A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
title_full A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
title_fullStr A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
title_full_unstemmed A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
title_short A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
title_sort human natural antibody to adenocarcinoma that inhibits tumour cell migration.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063195/
https://www.ncbi.nlm.nih.gov/pubmed/9823972
work_keys_str_mv AT kodak ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT nakajiman ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT saiton ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT yasutomij ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT mcknightme ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT glassymc ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT kodak humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT nakajiman humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT saiton humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT yasutomij humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT mcknightme humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration
AT glassymc humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration